

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Antengene Corporation Limited

德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6996)

INSIDE INFORMATION

GLOBAL LICENSE AGREEMENT BETWEEN ANTENGENE AND UCB FOR ATG-201, A CD19/CD3 BISPECIFIC T-CELL ENGAGER FOR AUTOIMMUNE DISEASES

This announcement is made by Antengene Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on March 3, 2026, Antengene Biologics Limited and Antengene (Hangzhou) Biologics Co., Ltd., both are the wholly-owned subsidiaries of the Company (collectively, the “**Licensor**”), entered into a license agreement (the “**License Agreement**”) with UCB (“**UCB**”, or the “**Licensee**”), pursuant to which the Licensor will provide an exclusive, worldwide license to the Licensee to further develop, manufacture and commercialize ATG-201 (“**ATG-201**”) and access to its associated manufacturing technology in relation to ATG-201. In return, the Licensor will receive an upfront and near-term milestone payment of USD80 million (comprising an initial upfront payment of USD60 million and additional near-term milestone payments of USD20 million upon satisfaction of certain conditions), and will be eligible to receive future success-based development and commercial milestone payments of up to approximately USD1.1 billion, as well as tiered royalties on future net sales.

ATG-201 is an investigational CD19/CD3 bispecific T-cell engager (TCE) designed and developed for the treatment of B cell-related autoimmune diseases. The Licensor plans to submit clinical trial applications for ATG-201 in China and Australia in the first quarter of 2026. The Licensor will complete first-in-human phase 1 studies in these two jurisdictions, and thereafter transfer further ATG-201 clinical and other development to the Licensee.

The shares of the Licensee are listed on the Euronext Brussels (symbol: “UCB”). Founded in 1928, the Licensee is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. With more than 9,000 people in approximately 40 countries, the Licensee generated revenue of €7.7 billion in 2025.

The Company will leverage on this opportunity to continue developing the Group’s technology platforms and maximize its scientific and commercial value. Based on the above, the Board believes that the entering into of the License Agreement is in the best interests of the Company and its shareholders as a whole.

LISTING RULES IMPLICATIONS

The transactions contemplated under the License Agreement are of a revenue nature in the ordinary and usual course of business of the Group and do not constitute any notifiable transactions or connected transactions of the Company under Chapter 14 and 14A of the Listing Rules.

The Group cannot guarantee that ATG-201 will ultimately be successfully developed and marketed. **Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By the Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, March 4, 2026

As at the date of this announcement, the board of Directors comprises Dr. Jay Mei and Mr. Donald A. Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.

About Antengene

Antengene Corporation Limited (“**Antengene**”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 × CD3 (ATG-201 for B cell-related autoimmune diseases), CDH6 × CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 × CD3 (ATG-112 for gynecologic tumors and non-small cell lung cancer), LY6G6D × CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D × CD3 (ATG-021 for multiple myeloma), LILRB4 × CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 × CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug applications (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9,000 people in approximately 40 countries, the company generated revenue of € 7.7 billion in 2025. UCB is listed on the Euronext Brussels (symbol: “UCB”).

Forward-looking Statements

The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to The Stock Exchange of Hong Kong Limited.